HC Wainwright Lowers Keros Therapeutics (NASDAQ:KROS) Price Target to $47.00

Keros Therapeutics (NASDAQ:KROS) had its price objective lowered by analysts at HC Wainwright from $100.00 to $47.00 in a research note issued on Friday, Marketbeat reports. The firm currently has a “buy” rating on the stock. HC Wainwright’s price target suggests a potential upside of 149.60% from the stock’s current price.

A number of other equities analysts have also recently commented on KROS. William Blair cut Keros Therapeutics from an “outperform” rating to a “market perform” rating in a report on Thursday. Guggenheim reaffirmed a “buy” rating and issued a $102.00 price objective (up previously from $96.00) on shares of Keros Therapeutics in a research note on Wednesday, December 4th. Bank of America cut their price objective on Keros Therapeutics from $81.00 to $76.00 and set a “buy” rating for the company in a research note on Thursday, September 12th. Wedbush restated an “outperform” rating and set a $84.00 target price on shares of Keros Therapeutics in a research note on Thursday, November 7th. Finally, Scotiabank started coverage on shares of Keros Therapeutics in a research report on Wednesday, October 16th. They issued a “sector outperform” rating and a $77.00 price target for the company. Three investment analysts have rated the stock with a hold rating and eleven have issued a buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $85.67.

Keros Therapeutics Price Performance

Shares of NASDAQ KROS opened at $18.83 on Friday. The firm has a 50-day moving average of $59.11 and a 200 day moving average of $52.65. Keros Therapeutics has a 1 year low of $15.67 and a 1 year high of $73.00. The stock has a market cap of $762.75 million, a P/E ratio of -3.61 and a beta of 1.20.

Keros Therapeutics (NASDAQ:KROS) last issued its quarterly earnings data on Wednesday, November 6th. The company reported ($1.41) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.28) by ($0.13). The company had revenue of $0.39 million for the quarter. Keros Therapeutics had a negative net margin of 27,890.94% and a negative return on equity of 41.74%. The firm’s revenue for the quarter was up 4750.0% compared to the same quarter last year. During the same quarter last year, the business posted ($1.33) EPS. Research analysts expect that Keros Therapeutics will post -5.26 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in KROS. Point72 Asset Management L.P. increased its holdings in shares of Keros Therapeutics by 155.9% in the third quarter. Point72 Asset Management L.P. now owns 947,570 shares of the company’s stock worth $55,025,000 after purchasing an additional 577,220 shares during the last quarter. Alkeon Capital Management LLC boosted its stake in Keros Therapeutics by 18.7% during the third quarter. Alkeon Capital Management LLC now owns 1,897,601 shares of the company’s stock valued at $110,194,000 after buying an additional 298,694 shares during the last quarter. Parkman Healthcare Partners LLC grew its holdings in Keros Therapeutics by 112.3% during the 3rd quarter. Parkman Healthcare Partners LLC now owns 421,782 shares of the company’s stock valued at $24,493,000 after buying an additional 223,155 shares in the last quarter. Assenagon Asset Management S.A. increased its stake in Keros Therapeutics by 814.6% in the 3rd quarter. Assenagon Asset Management S.A. now owns 223,704 shares of the company’s stock worth $12,990,000 after acquiring an additional 199,245 shares during the last quarter. Finally, FMR LLC boosted its position in shares of Keros Therapeutics by 3.8% during the 3rd quarter. FMR LLC now owns 4,899,134 shares of the company’s stock valued at $284,493,000 after acquiring an additional 179,374 shares during the last quarter. Institutional investors own 71.56% of the company’s stock.

About Keros Therapeutics

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.